NCT05646550View on ClinicalTrials.gov

Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Prostate Cancer Recurrent

Interventions

DRUG

CC-1 Infusion

Short term (3h) infusion of CC-1

Trial Locations (1)

72076

RECRUITING

University Hospital Tuebingen, Tübingen

All Listed Sponsors

lead

University Hospital Tuebingen

OTHER